Geneva, Switzerland and Boston, MA – February 22, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN),
a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious
conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be
participating in two upcoming investor conferences.
- The SVB Leerink Global Healthcare Conference taking place in New York February 27-March 1, 2019. ObsEva will present on
Thursday, February 28, 2019, at 3 p.m. Eastern Time.
- The Jefferies Global Healthcare Summit taking place in Zurich, Switzerland on March 8, 2019. ObsEva will present on Friday,
March 8, 2019 at 3:45 p.m. Central European Time.
The SVB Leerink presentation will be webcast, and available in the “Investors” section of ObsEva’s website
www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization
of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic
in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs
focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ
Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the
ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile
Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4017 Office
+1 646 537 5649 Mobile
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
